An analysis of which subgroups of multiple myeloma patients, divided according to β2-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy

Haematologica

Volumn 84, Issue 10, 1999, Pages 905-910

  Boccadoro, Mario ^a   Tarella, Corrado ^a   Palumbo, Antonio ^a   Argentino, Chiara ^a   Triolo, Sabrina ^a   Dominietto, Alida ^a   Callea, Vincenzo ^c   Lauta, Vito Michele ^c   Molica, Stefano ^c   Musto, Pellegrino ^c   Marmont, Filippo ^c   Gianni, A Massimo ^b   Pileri, Alessandro ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NONE

Author keywords

2 microglobulin; Autologous transplantation; Labeling index; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; LABELING INDEX; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PLASMA CELL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; CELL COUNT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032728628     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Boccadoro M, Pileri A. Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematol Oncol Clin North Am 1997; 11:111-31.
2. MyelomaTrialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomised trials. J Clin Oncol 1998; 16:3832-42.
3. Barlogie B, Jagannath S, Dixon D, et al. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 1990; 76:677-80.
4. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93:55-65.
5. San Miguel J, Creixenti JB, Garcia-Sanz R. Treatment of multiple myeloma. Haematologica 1999; 84:36-58.
6. Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 8663:580-4.
7. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80:1666-72.
8. Corradini P, Voena C, Astolfi M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85:1596-602.
9. Corradini P, Voena C, Tarella C, et al. Molecular and clinical remission in multiple myeloma: the role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17:208-15.
10. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335:91-7.
11. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89:789-93.
12. Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94:1248-53.
13. Bladé J, San Miguel JF, Fontanillas M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol 1996; 14:2167-73.
14. Alexanian R, Dimopoulos MA, Hester J, Delasalle KB, Champlin R. Early myeloablative therapy for multiple myeloma. Blood 1994; 84:4278-82.
15. Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin R. Limited value of myeloablative therapy for late multiple myeloma. Blood 1994; 83:512-6.
16. Vesole DH, Tricot G, Jagannath S, et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88:838-47.
17. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86:4250-6.
18. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85:588-96.
19. Gianni AM, Tarella C, Bregni M, et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 1994; 12:503-9.
20. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36:842-54.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
22. Omedè P, Tarella C, Palumbo A, et al. Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. Br J Haematol 1997; 99:685-91.
23. Boccadoro M, Palumbo A, Argentino C, et al. Conventional induction treatments do not influence overall survival in multiple myeloma. Br J Haematol 1997; 96:333-7.
24. Anderson KC, Hamblin TJ, Traynor A. Management of multiple myeloma today. Semin Hematol 1999; 36:3-8.
25. Henon P, Donatini B, Eisemann JC, Becker M, BeckWirth C. Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma. Bone Marrow Transplant 1995; 16:19-25.
26. 2-microglobulin in monoclonal gammopathies. Acta Haematol 1987; 78:239-42.
27. 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72:219-23.
28. Boccadoro M, Marmont F, Tribalto M, et al. Early responder myeloma: kinetic studies identify a patient subgroup characterized by a very poor prognosis. J Clin Oncol 1989; 7:119-25.
29. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336:1290-7.